[Warm autoimmune hemolytic anemias and Evans syndrome in adults].
OBJECTIVE
The outcome of autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES) in adults is not well-known and their management is mainly based on empirical data.


BACKGROUND
The main characteristics of both AIHA and ES are reviewed in this article, based on the data available in the literature and on our experience. Although controlled studies and evidence-based data are lacking, some recommendations regarding the minimal workup useful to search for an underlying disease can be made as well as proposals for a better therapeutic strategy of both disorders.


CONCLUSIONS
A better knowledge of the mechanisms triggering AIHA and ES as well as therapeutic trials are needed in order to better stratify treatment taking into account the promising efficacy of rituximab.
Michel
M
M
Service de médecine interne, centre de référence pour les cytopénies auto-immunes de l'adulte, CHU Henri-Mondor, 52, avenue du maréchal de Lattre-de-Tassigny, 94010 Créteil, France. marc.michel@hmn.aphp.fr <marc.michel@hmn.aphp.fr>
D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D001323:Autoantibodies / Q000276:immunology*; D006801:Humans; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy
D001323:Autoantibodies